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Nociceptin/orphanin FQ (N/OFQ) is involved in many behavioural patterns; in particular, it exerts a modulating effect on nociception.
Like other proposed antiopiates, nociceptin/orphanin FQ has been shown to have analgesic, hyperalgesic as well as antianalgesic properties.
Among the various effects proposed on nociceptive sensitivity at supraspinal level, the antagonistic activity toward morphine analgesia seems
to be of interest. Therefore, we decided to investigate whether nociceptin/orphanin FQ and [Arg14, Lys15] nociceptin/orphanin FQ (R-K, a
nociceptin analogue) can have the same effect on the analgesia produced by nonopioid analgesics. In this study, we examined the
antianalgesic effect of nociceptin/orphanin FQ and its analogue R-K on paracetamol-induced analgesia and evaluated by means of the hot
plate test in rats. Nociceptin/orphanin FQ was intracerebroventricularly administered, and, after 5 min, a dose of 400 mg/kg paracetamol was
injected intraperitoneally, 30 min before the hot plate test. Nociceptin/orphanin FQ and R-K showed a dose-dependent antagonism on the
antinociceptive effect of paracetamol, and the activity of both drugs was significantly reduced by the antagonist [Nphe1] Arg14, Lys15–N/
OFQ–NH2 (UFP-101). These data indicate that nociceptin/orphanin FQ and R-K have an antianalgesic effect on the analgesia produced by a
nonopioid analgesic drug, like paracetamol, that seems to develop within the brain.
D 2004 Elsevier B.V. All rights reserved.
Keywords: N/OFQ (nociceptin/orphanin FQ); R-K, paracetamol; UFP-101; Analgesia; Hot plate test1. Introduction
Nociceptin/orphanin has been identified as a potent
endogenous agonist of ORL1 receptors currently named as
NOP receptor (Cox et al., 2000). This 17-amino acid peptide
shares a structure related to the peptide dynorphin A 1–17
(Julius, 1995). The NOP receptor was identified as a G-
protein-coupled receptor that mediates the inhibition of
adenyl cyclase (Meunier et al., 1995), the reduction of
calcium channel conductance (Connor et al., 1996) and the
activation of potassium channels (Vaugham and Christie,0014-2999/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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E-mail address: sandrini.maurizio@unimore.it (M. Sandrini).1996). NOP receptor signalling is involved in several spinal
and supraspinal actions, including opiate tolerance, depend-
ence/withdrawal, adaptive response to anxiety and stress,
reward, memory and pain (for a review, see Meis, 2003).
The action on pain modulation seems to differ at spinal and
supraspinal levels, creating in turn hyperalgesia, analgesia
or antianalgesia, although evidence of the reported phenom-
ena is not equally robust (Mogil and Pasternak, 2001). The
supraspinal hyperalgesic action of nociceptin/orphanin FQ
(N/OFQ) is transient compared with the antianalgesic
action, the former lasting only 15–30 min and the latter
being long-lasting (Candeletti and Ferri, 2000). Moreover, a
functional antiopioid activity of nociceptin/orphanin FQ has
been described (Mogil et al., 1996); when intracerebroven-
tricularly (i.c.v.) injected, nociceptin/orphanin FQ canology 507 (2005) 43–48
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spinal A-opioid receptors, including morphine (Lufty et al.,
1999) and y- and n-opioid agonists (Wang et al., 1999; Zhu
et al., 1998). Finally, it has been shown that nociceptin/
orphanin FQ inhibits the neurotransmitter release in several
nuclei within the central nervous system (CNS) in vivo and
in vitro; in particular, it modulates 5-hydroxytryptamine (5-
HT) and noradrenaline efflux in synaptosomal preparation,
chiefly in the cerebral cortex (Schlicker and Morari, 2000;
Marti et al., 2003).
Many reports indicate that paracetamol exerts its
antinociceptive activity by acting within the CNS, both at
spinal and supraspinal levels, as well as peripherally
(McCormack, 1994; Bjo¨rkman, 1995). It has been suggested
that a number of neurotransmitter systems may be involved
in the central analgesic activity of paracetamol. In particular,
the 5-HT pathways seem to play a pivotal role in the way
this drug behaves (Pellissier et al., 1995; Pini et al., 1996).
In our previous work, we demonstrated the importance of
the central serotonergic system in the antinociceptive effect
of paracetamol, matching an increase in serotonin levels and
a decrease in the number of 5-HT2 receptors in the cerebral
cortex of the rat (Pini et al., 1996). On the basis of the above
results, we decided to investigate the possible antagonistic
effect of nociceptin/orphanin FQ and its analogue [Arg14,
Lys15] nociceptin/orphanin FQ (R-K) on paracetamol-
induced antinociception in the hot plate test in the rat to
establish whether a pretreatment with [Nphe1] Arg14, Lys15–
N/OFQ–NH2 (UFP-101, a specific NOP receptor antagonist,
Calo` et al., 2002) could revert the action of the two peptides
on paracetamol activity.2. Methods
2.1. Animals and surgery
Male Wistar rats weighing 180–200 g were housed in
PlexiglasR cages in groups of three–four in controlled
conditions (free access to food and water; 12-h dark/light
cycle; temperature, 22F1 8C; humidity, 60%). The ethical
guidelines for investigation of experimental pain in con-
scious animals were followed, and procedures were carried
out according EEC ethical regulations for animal research
(EEC Council 86/609; D.Lgs. 27/01/1992, No. 116).
The rats were randomly divided into groups of eight
animals each. For i.c.v. administrations, stainless-steel guide
cannulae (23 ga; Plastic One, Roanoke, VA, USA) were
stereotaxically implanted in the right lateral ventricle to a
depth of 0.5 mm above the ventricle (in millimeters from the
bregma: AP=0.8; L=1.4; V=3.25) (Paxinos and Watson,
1997) under ketamine plus xylazine anesthesia (115+2 mg/
kg i.p.; Farmaceutici Gellini, Aprilia, Italy and Bayer, Milan,
Italy, respectively) and fixed in place with acrylic dental
cement and one skull screw. A removable plug was kept in
place except during the drug injections. After 5–7 days ofrecovery, the animal were subjected to an unheated plate
test, and animal with alterations of gross behaviour were
discarded. All i.c.v. injections were in a volume of 5 Al.
After the end of the experiment, rats were i.c.v. injected with
5 Al of dye (Evans blue) and sacrificed under anesthesia. The
correct placement of the cannulae was ascertained by
inspection of dye diffusion in the right lateral ventricle.
2.2. Treatment
Nociceptin/orphanin FQ, at the doses of 1, 5 and 10
nmol, R-K, at the doses of 0.1, 0.2, 0.5 and 2 nmol, or saline
were intracerebroventricularly (i.c.v.) injected by means of
an indwelling cannula (1 mm longer than the guide cannula)
5 min before paracetamol (400 mg/kg i.p.; dissolved in
vehicle, which consisted of 12.5% of 1,2-propanediol in
sterile saline) or vehicle, and the animals were subjected to
the hot plate test 30 min later. This dose of paracetamol had
proved effective in dose–response experiments under
identical experimental conditions (Pini et al., 1996). Other
groups of rats were administered with UFP-101 (10 and 20
nmol) 5 min before nociceptin/orphanin FQ or R-K plus
paracetamol, or paracetamol alone, according to the above
experimental schedule.
2.3. Hot plate test
The hot plate consisted of an electrically heated surface
(Socrel DS-35, Ugo Basile, Comerio, VA, Italy) kept at a
constant temperature of 54F0.4 8C. The latencies for paw-
licking or jumping were recorded for each animal. The
analgesic efficacy of the drug was evaluated as a percentage
of the maximum possible effect (%MPE) according to the
formula (TL BL)/(45BL)100, where TL-test latency,
BL-baseline latency, 45-cut-off time in seconds.
2.4. Motor activity
Spontaneous coordinate activity was measured in a
soundproof room by means of an activity analyser equipped
with IR beam-array cages (Ugo Basile). The number of
horizontal movements was recorded 30 min after the last
treatment in rats receiving nociceptin/orphanin FQ (10
nmol) alone, R-K (0.5 nmol) alone, nociceptin/orphanin
FQ or R-K in combination with paracetamol (400 mg/kg),
saline, and those pretreated with UFP-101 (20 nmol). The
number of impulses was continuously recorded for 5 min.
2.5. Drugs
Paracetamol was purchased from Sigma-Aldrich (Milan,
Italy); the heptadecapeptide nociceptin/orphanin FQ (Phe–
Gly2–Phe–Thr–Gly–Ala–Arg–Lys–Ser–Ala–Arg–Lys–Leu–
Ala–Asn–Gln) from Bakem—UK, Merseyside, UK; [Arg14,
Lys15] nociceptin/orphanin FQ (R-K) and [Nphe1] Arg14,
Lys15–N/OFQ–NH2 (UFP-101) synthesised as described
Fig. 1. Effect of nociceptin/orphanin FQ (N/OFQ, 1, 5 and 10 nmol/rat,
i.c.v.) on the antinociceptive action of paracetamol (PARA, 400 mg/kg, i.p.)
in the hot plate test: two-way ANOVA, F(7–56)=4.97, Pb0.01; influence of
UFP-101 (UFP, 10 and 20 nmol/rat, i.c.v.) thereon: three-way ANOVA,
F(13–104)=3.36, Pb0.01. PARAwas administered 5 min after N/OFQ, and
the rats were tested 30 min later. Pretreatment experiments were performed
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and Dr. G. Calo` (University of Ferrara, Italy).
2.6. Statistical analysis
The data obtained from the hot plate and motor activity
experiments were expressed as meansFS.E.M. A two-way
analysis of variance (ANOVA) was used to analyse the
effect of nociceptin/orphanin FQ or R-K pretreatment,
paracetamol treatment and their interaction followed by
22 factorial analysis by means of orthogonal comparisons.
A three-way ANOVA using the program package SPSS
11.0 (SPSS Chicago, IL, USA) was performed to examine
the effect of paracetamol, nociceptin/orphanin FQ, R-K,
UFP-101 treatment and their interaction in the hot plate test
and in motor activity analysis. The Bonferroni post hoc test
was used for both the two-way and three-way ANOVA
when the effects of nociceptin/orphanin FQ, R-K, UFP-101
and paracetamol have been separately evaluated. The level
of significance was set at 0.05.
injecting UFP-101, 5 min before N/OFQ; PARA was administered 5 min
later. Each point represents the percentage of the maximum possible effect
(%MPE); values were expressed as meanFS.E.M. of eight rats for each
group. Controls-saline (SAL)+SAL+vehicle (VEH; consisting of 12.5% of
1,2-propanediol in sterile saline)-treated rats. Data of the two experiments
have been gathered in this figure to sum them up. *Pb0.05 vs. control
values; #Pb0.05 vs. SAL+SAL+PARA values (ANOVA followed by
Bonferroni test). Note: the effect of UFP-101 pretreatment on para-
cetamol-induced antinociception is shown by the left end points of the lines
corresponding to UFP 10 (or UFP 20)+N/OFQ+PARA, where the dose of
N/OFQ is equal to 0.3. Results
Paracetamol (400 mg/kg) significantly increased the
%MPE values in the hot plate test, as expected. Nocicep-
tin/orphanin FQ did not change the %MPE values at any
dose used (Fig. 1). At the doses of 1 and 5 nmol, nociceptin/
orphanin FQ reduced the antinociceptive effect of para-
cetamol at different degrees. Nociceptin/orphanin FQ (1
nmol) plus paracetamol values were significantly different
from control values and did not differ from paracetamol
(alone) values. The interaction test showed no significance.
The dose of 5 nmol had an antagonistic effect on the
paracetamol activity, the interaction test showing signifi-
cance. The highest dose used of nociceptin/orphanin FQ
completely abolished the effect of paracetamol. The %MPE
values were no different from those of controls, with the
interaction test showing high significance.
The effect of nociceptin/orphanin FQ was dose-depend-
ent since the increase in %MPE values induced by
paracetamol was completely blocked by the highest dose
of the neuropeptide, while the effect of paracetamol was
reduced by the two lower doses (30.1% and 56,7% for 1
and 5 nmol, respectively).
Then, we investigated whether a pretreatment with UFP-
101 (10 and 20 nmol) was able to prevent the antagonistic
effect of nociceptin/orphanin FQ on paracetamol-induced
antinociception, evaluating data by means of the three-way
ANOVA.
UFP-101 was not able to modify the basal nociception
(%MPE: 5.45F2.37 and 5.67F2.83 for 10 and 20 nmol,
respectively, vs. 1.24F0.62 for controls; PN0.05, not
shown). Furthermore, paracetamol-induced nociception
remained unchanged by UFP-101 at any dose used (Fig.
1, see note). The latter result was confirmed by the lack ofinteraction for UFP-101paracetamol treatment. ANOVA
showed no significant main effect for paracetamol treat-
ment, nociceptin/orphanin FQ (10 nmol) injection and
UFP-101 (10 and 20 nmol) pretreatment. A significant
UFP-101nociceptin/orphanin FQ treatment interaction
was observed for both the doses of UFP-101 used, F(1–
104)=5.38, Pb0.05 and F(1–104)=7.43, Pb0.01, respec-
tively. Furthermore, the UFP-101nociceptin/orphanin
FQparacetamol treatment interaction showed signifi-
cance, F(1–104)=6,74, Pb0.05 and F(1–104)=7.98,
Pb0.01, for 10 and 20 nmol UFP-101, respectively.
A more detailed analysis using the Bonferroni test
indicated that, at the dose of 10 nmol, UFP-101 partially
reverted while, at the dose of 20 nmol, significantly
prevented the antagonistic effect of the dose of 10 nmol
nociceptin/orphanin FQ on paracetamol-induced antinoci-
ception in the hot plate test (42.1%) (Fig. 1).
The effect of nociceptin/orphanin FQ analogue, [Arg14,
Lys15] nociceptin/orphanin FQ (R-K), was then compared
with the parent compound. R-K, given alone, slightly but not
significantly increased the %MPE values with respect to the
controls only at the higher doses (0.5 and 2 nmol). R-K
showed an effect similar to that of nociceptin/orphanin FQ on
paracetamol-induced analgesia, but it differed in potency
(Fig. 2). At the doses of 0.5 and 2 nmol, R-K completely
 Fig. 2. Effect of R-K (0.1, 0.2, 0.5 and 2 nmol/rat, i.c.v.) on the
antinociceptive action of paracetamol (PARA, 400 mg/kg, i.p.) in the hot
plate test: two-way ANOVA, F(9–72)=3.23, Pb0.01; influence of UFP-101
(UFP, 10 and 20 nmol/rat, i.c.v.) thereon: three-way ANOVA, F(9–
72)=3.75, Pb0.01. PARA was administered 5 min after R-K, and the rats
were tested 30 min later. Pretreatment experiments were performed
injecting UFP-101, 5 min before R-K; PARA was administered 5 min
later. Each point represents the percentage of the maximum possible effect
(%MPE); values were expressed as meanFS.E.M. of eight rats for each
group. Controls-saline (SAL)+SAL+vehicle (VEH; consisting in 12.5% of
1,2-propanediol in sterile saline)-treated rats. Data of the two experiments
have been gathered in this figure to sum them up. *Pb0.05 vs. control
values; #Pb0.05 vs. SAL+SAL+PARA values (ANOVA followed by
Bonferroni test). Note: the effect of UFP-101 pretreatment on para-
cetamol-induced antinociception is shown by the left end points of the lines
corresponding to UFP 10 (or UFP 20)+R-K+PARA, where the dose of R-K
is equal to 0.
Table 2
Influence of R-K (0.5 nmol/rat, i.c.v.), UFP-101 (UFP, 20 nmol/rat, i.c.v.)
and/or paracetamol (PARA, 400 mg/kg, i.p.) on motor activity in rats
Treatment N8 of movements
Controls 142.75F62.93
SAL+R-K 0.5+VEH 121.27F30.98
UFP-101 20+SAL+VEH 169.23F29.11
SAL+SAL+PARA 137.34F24.38
UFP 20+SAL+PARA 153.27F21.81
SAL+R-K 0.5+PARA 120.28F29.76
UFP 20+R-K 0.5+PARA 144.22F30.12
The analysis was performed 30 min after the last treatment. The number of
horizontal movements was recorded continuously for 5 min and expressed
as meanFS.E.M. of eight rats. The three-way ANOVA showed no
significance: F(6–49)=0.24, P=0.96.
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used (0.1 nmol) was ineffective. The dose of 0.2 nmol had an
intermediate effect since it decreased the %MPE values by
48.5% towards paracetamol values. The interaction test
showed significance for the three higher doses, indicating
that, even in the case of R-K, the antagonistic effect was dose-
dependent. To analyse the effect of the pretreatment with
UFP-101 on the R-K activity, we utilized the three-way
ANOVA. No significant main effect was found for para-
cetamol treatment, R-K (0.5 nmol) injection and UFP-101Table 1
Influence of nociceptin/orphanin FQ (N/OFQ, 10 nmol/rat, i.c.v.), UFP-101
(UFP, 20 nmol/rat, i.c.v.) and/or paracetamol (PARA, 400 mg/kg, i.p.) on
motor activity in rats
Treatment N8 of movements
Controls 150.38F51.48
SAL+N/OFQ 10+VEH 134.81F28.43
UFP 20+SAL+VEH 177.14F27.76
SAL+SAL+PARA 148.34F25.92
UFP 20+SAL+PARA 153.27F21.81
SAL+N/OFQ 10+PARA 130.32F27.56
UFP 20+N/OFQ 10+PARA 158.42F60.52
The analysis was performed 30 min after the last treatment. The number of
horizontal movements was recorded continuously for 5 min and expressed
as meanFS.E.M. of eight rats. The three-way ANOVA showed no
significance: F(6–49)=0.17, P=0.98.(10 and 20 nmol) pretreatment. A significant interaction
was found for UFP-101 (20 nmol)R-K, F(1–72)=4.56,
Pb0.05, but no interaction was detected for the dose of
10 nmol of UFP-101. UFP-101R-Kparacetamol treat-
ment showed significant interaction using the dose of
20 nmol UFP-101, F(1–72)=4.12, Pb0.05, while the
interaction was not present at the lower dose. As for
nociceptin/orphanin FQ, no significant interaction was found
for UFP-101paracetamol treatment at any dose used (Fig. 2,
see note). The Bonferroni analysis demonstrated that UFP-
101, at doses of 10 and 20 nmol, partially prevented the action
of R-K (0.5 nmol) on paracetamol: only the highest dose had
an antagonistic effect, and the %MPE values were not
significantly different from those of paracetamol alone,
although they were different from those of controls. On the
other hand, UFP-101 (10 nmol)+R-K+paracetamol values
differed from those of paracetamol alone but not from control
values (Fig. 2).
Nociceptin/orphanin FQ (10 n mol) and R-K (0.5 nmol)
slightly decreased the motor activity 30 min after the final
treatment, while paracetamol had no effect on locomotion
and did not modify the effect of either nociceptin/orphanin
FQ or R-K. Finally, UFP-101 (20 nmol) slightly increased
the number of movements 40 min thereafter but had no
effect on paracetamol. None of the effect reached signifi-
cance (Tables 1 and 2).4. Discussion
In the present study, we have demonstrated that
nociceptin/orphanin FQ and its analogue R-K are able to
antagonize in a dose-dependent manner the antinociceptive
effect of paracetamol in the hot plate test. Previously,
several authors reported that nociceptin/orphanin FQ was
able to prevent the morphine-induced analgesia after i.c.v.
injection, showing opiate-modulating properties (Mogil et
al., 1996; Lufty et al., 1999; Harrison and Grandy, 2000).
Little or no information is available about the effect of
nociceptin/orphanin FQ and its analogues on the antinoci-
ceptive activity of nonopioid analgesics. The activity of
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assay used to measure effect at peripheral, spinal and
supraspinal levels. It has already been demonstrated that
i.c.v. injected nociceptin/orphanin FQ elicits an antianalge-
sic effect in thermal and electrical assays (Mogil and
Pasternak, 2001). The hot plate, heated to a constant
temperature, produces two behavioural components that
can be measured in term of reaction times, namely, licking
and jumping; both are considered to be supraspinally
integrated responses (Le Bars et al., 2001). This prompted
us to use this test in our work, and our data confirm the
relevance of the central component of the mechanism of
action of paracetamol, suggesting that the interaction
between nociceptin/orphanin FQ and paracetamol can occur
within the brain.
Many data indicate that locomotion may influence
nociception, but the changes have not always been well
elucidated (Le Bars et al., 2001). However, we evaluated
motility after treatment with the drugs used, both alone or in
combination.
The antagonistic effect of nociceptin/orphanin FQ on
paracetamol-induced antinociception described in this work
does not seem to depend on the nociceptin/orphanin FQ-
induced decrease in motor activity (Devine et al., 1996)
since a decrease in locomotion could potentially prolong the
hot plate reaction times and so apparently increase the
antinociceptive effect of paracetamol, while nociceptin/
orphanin FQ showed the opposite effect.
The nociceptin/orphanin FQ analogue, R-K, showed an
antagonistic effect on paracetamol antinociception at doses
about 20 times lower than those of nociceptin/orphanin FQ,
indicating that the potency of nociceptin/orphanin FQ can
be increased by little changes of the amino acid sequence.
On the basis of some literature data, we hypothesize a
main role for serotonin in the antagonistic effect of
nociceptin/orphanin FQ towards paracetamol antinocicep-
tion. In fact, the antinociceptive effect of paracetamol is
mediated by serotonin, both at spinal (Pelissier et al., 1996;
Courade et al., 2001) and supraspinal levels (Pini et al.,
1997). Secondly, in vitro studies showed that paracetamol
enhanced the K+-evoked overflow of [3H]–5-HT, thus
indicating that paracetamol affects central serotonergic
neurotransmission (Courade et al., 2001). On the other
hand, recent data described a modulation of [3H]–5-HT
release by nociceptin/orphanin FQ in synaptosomes of the
rat cortex (Sbrenna et al., 2000; Marti et al., 2003). Hence, a
relationship between the two results could occur, and it
could explain the antagonism exerted by nociceptin/orpha-
nin FQ on the antinociceptive effect of paracetamol.
Nociceptin/orphanin FQ as well as R-K actions take place
at their (NOP) receptor level since they were affected by a
pretreatment with UFP-101 that partially but significantly
prevented the antagonistic effect of both nociceptin/orphanin
FQ and R-K on the antinociceptive effect of paracetamol in
our experimental conditions. UFP-101 is a competitive
antagonist of the NOP receptor and is able to antagonizemany of the effects induced by nociceptin/orphanin FQ in
vivo, including its analgesic activity (Corradini et al., 2001).
Moreover, it prevented the inhibition of synaptosomial K+-
evoked [3H]–5-HT release induced by agonists of NOP
receptors, while it was inactive if administered alone (Calo` et
al., 2002). This last observation may explain the lack of
influence of UFP-101 on paracetamol antinociception
observed in the present study.
On the other hand, an antidepressant-like effect of UFP-
101, possibly related to a potentiation of monoaminergic (in
particular serotonergic) neurotransmission, has been
reported (Gavioli et al., 2004). The only limited and
nonsignificant (although dose-related) increase of para-
cetamol antinociception caused by UFP-101 observed in
this study could mean a different relevance of the inhibitory
actions of endogenous N/OFQ on serotonergic pathways
related to pain modulation or to mood control.
In conclusion, this study shows an antagonistic effect of
nociceptin/orphanin FQ and its analogue R-K on para-
cetamol-induced nociception with an action involving the
NOP receptor. These results extend the knowledge on the
antianalgesic role of nociceptin that has been until now
largely (if not exclusively) related to opioid-induced
analgesia.
Even if we cannot exclude other possible mechanisms of
interaction between nociceptin and paracetamol, we suggest
that serotonin might play a relevant role in this interaction
since nociceptin/orphanin FQ and paracetamol have an
opposite effect on serotonin levels at least in the cerebral
cortex (Mela et al., 2004).Acknowledgements
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